209 related articles for article (PubMed ID: 11392450)
1. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel.
Bruno R; Vivier N; Veyrat-Follet C; Montay G; Rhodes GR
Invest New Drugs; 2001 May; 19(2):163-9. PubMed ID: 11392450
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Bruno R; Hille D; Riva A; Vivier N; ten Bokkel Huinnink WW; van Oosterom AT; Kaye SB; Verweij J; Fossella FV; Valero V; Rigas JR; Seidman AD; Chevallier B; Fumoleau P; Burris HA; Ravdin PM; Sheiner LB
J Clin Oncol; 1998 Jan; 16(1):187-96. PubMed ID: 9440742
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization.
Veyrat-Follet C; Bruno R; Olivares R; Rhodes GR; Chaikin P
Clin Pharmacol Ther; 2000 Dec; 68(6):677-87. PubMed ID: 11180028
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.
Pronk LC; Stoter G; Verweij J
Cancer Treat Rev; 1995 Sep; 21(5):463-78. PubMed ID: 8556719
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel (Taxotere) in the treatment of cancer.
Burris HA
Semin Oncol; 2000 Apr; 27(2 Suppl 3):1-2. PubMed ID: 10810931
[No Abstract] [Full Text] [Related]
6. Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.
Fukae M; Shiraishi Y; Hirota T; Sasaki Y; Yamahashi M; Takayama K; Nakanishi Y; Ieiri I
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1013-1023. PubMed ID: 27709284
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials.
Bruno R; Riva A; Hille D; Lebecq A; Thomas L
Am J Health Syst Pharm; 1997 Dec; 54(24 Suppl 2):S16-9. PubMed ID: 9435928
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of docetaxel.
Clarke SJ; Rivory LP
Clin Pharmacokinet; 1999 Feb; 36(2):99-114. PubMed ID: 10092957
[TBL] [Abstract][Full Text] [Related]
9. Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
Freyer G; Hennebert P; Awada A; Gil T; Kerger J; Selleslags J; Brassinne C; Piccart M; de Valeriola D
Clin Cancer Res; 2002 Jan; 8(1):95-102. PubMed ID: 11801544
[TBL] [Abstract][Full Text] [Related]
10. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
Pazdur R; Kudelka AP; Kavanagh JJ; Cohen PR; Raber MN
Cancer Treat Rev; 1993 Oct; 19(4):351-86. PubMed ID: 8106152
[TBL] [Abstract][Full Text] [Related]
11. The taxoids: paclitaxel and docetaxel.
Gelmon K
Lancet; 1994 Nov; 344(8932):1267-72. PubMed ID: 7967989
[No Abstract] [Full Text] [Related]
12. Docetaxel (taxotere) in the treatment of non-small cell lung cancer.
Georgoulias V
Curr Med Chem; 2002 Apr; 9(8):869-77. PubMed ID: 11966449
[TBL] [Abstract][Full Text] [Related]
13. Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.
Baille P; Bruno R; Schellens JH; Webster LK; Millward M; Verweij J; Montay G
Clin Cancer Res; 1997 Sep; 3(9):1535-8. PubMed ID: 9815840
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and metabolism of Taxotere (docetaxel).
Bruno R; Sanderink GJ
Cancer Surv; 1993; 17():305-13. PubMed ID: 7907950
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.
Fulton B; Spencer CM
Drugs; 1996 Jun; 51(6):1075-92. PubMed ID: 8736622
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel: current status and future prospects.
Eisenhauer E
J Clin Oncol; 1995 Dec; 13(12):2865-8. PubMed ID: 8523048
[No Abstract] [Full Text] [Related]
17. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
18. The development of docetaxel (Taxotere) in non-small cell lung cancer.
Kris MG; Miller VA; Ng KK; Grant SC
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-1-S14-4. PubMed ID: 9335515
[No Abstract] [Full Text] [Related]
19. [Chemotherapy of solid tumors: pharmacologic activity or effectiveness?].
Longo F; Mansueto G
Tumori; 1999; 85(6):A26-33. PubMed ID: 10774584
[No Abstract] [Full Text] [Related]
20. Docetaxel.
Cortes JE; Pazdur R
J Clin Oncol; 1995 Oct; 13(10):2643-55. PubMed ID: 7595719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
